Samarium for osteoblastic bone metastases and osteosarcoma

被引：34

作者：

Anderson, Pete ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Pediat, Houston, TX 77030 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 11期

关键词：

153Sm-EDTMP; bone cancer; bone metastases; bone scan; breast cancer; MIMvista fusion imaging software; osteosarcoma; prostate cancer; skeletal neoplasia; radiation therapy; radiopharmaceutical; radiosensitisation; sarnarium-153; lexidronam;

D O I：

10.1517/14656566.7.11.1475

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Samarium-153 lexidronam (Sm-153-EDTMP) is FDA approved for painful osteoblastic bone metastases that image on bone scan. Sm-153-EDTMP decay has a therapeutic p-emission and ay-photon for bone scan imaging. Monitoring of osteosarcoma radiation treatment effectiveness was performed with bone, CT, MRI and PET/CT fusion imaging. Bone scan and PET/CT improved in 5 out of 9 and 16 out of 18 osteosarcoma sites, respectively. Sm-153-EDTMP targets multiple sites of disease, with a single administration. Side effects of Sm-153-EDTMP (0.5 - 2.5 mCi/kg) have been minimal and include transient thrombocytopenia and neutropenia. 153Sm-EDTMP can be combined with radiation therapy, bisphosphonates and/or chemotherapy to synergistically improve palliation. This article reviews the rationale, indications and monitoring of standard-dose samarium and investigational high-dose Sm-153-EDTMP treatment of cancer involving bone.

引用

页码：1475 / 1486

页数：12

共 107 条

[51] Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases [J].

Janjan, NA ;

Payne, R ;

Gillis, T ;

Pololoff, D ;

Libshitz, HI ;

Lenzi, R ;

Theriault, R ;

Martin, C ;

Yasko, A .

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1998, 16 (03) :171-178

[52] Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen [J].

Kennedy, GA ;

Durrant, S ;

Butler, J ;

Morton, J ;

Western, R ;

Bartlett, ML ;

Allison, R ;

MacFarlane, DJ .

LEUKEMIA, 2005, 19 (05) :879-880

[53] SM-153 EDTMP AND RE-186-HEDP AS BONE THERAPEUTIC RADIOPHARMACEUTICALS [J].

KETRING, AR .

NUCLEAR MEDICINE AND BIOLOGY, 1987, 14 (03) :223-232

[54] Y-90 TREATMENT OF BONE METASTASES [J].

KUTZNER, J ;

GRIMM, W ;

BROD, KH ;

ROESLER, A .

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1982, 107 (36) :1360-1361

[55] A method for measurement of the uptake patterns of two beta-emitting radionuclides in the same tissue section with a digital silicon detector:: application to a study of 89SrCl2 and 153Sm-EDTMP in a dog with spontaneous osteosarcoma [J].

Kvinnsland, Y ;

Bruland, O ;

Moe, L ;

Skretting, A .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (02) :191-197

[56] 186Re_HEDP for metastatic bone pain in breast cancer patients [J].

Lam, MGEH ;

de Klerk, JMH ;

van Rijk, PP .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (Suppl 1) :S162-S170

[57]

Larsen RH, 2006, IN VIVO, V20, P325

[58]

LATTIMER JC, 1990, J NUCL MED, V31, P1316

[59]

LATTIMER JC, 1990, J NUCL MED, V31, P586

[60] COMPARISON OF BIOLOGICAL CHARACTERISTICS OF EDTMP COMPLEXES WITH TC-99M, IN-111 AND SM-153 IN RATS [J].

LAZNICEK, M ;

LAZNICKOVA, A ;

BUDSKY, F ;

PROKOP, J ;

KOPICKA, K .

APPLIED RADIATION AND ISOTOPES, 1994, 45 (09) :949-953

← 1 2 3 4 5 6 7 8 9 10 →